Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
© Wang et al. 2016
Received: 1 July 2015
Accepted: 3 February 2016
Published: 16 February 2016
The Erratum to this article has been published in Cancer Cell International 2016 16:38
The most common genetic changes identified in human NSCLC are Kras mutations (10–30 %) and p53 mutation or loss (50–70 %). Moreover, NSCLC with mutations in Kras and p53 poorly respond to current therapies, so we are trying to find a new target for the treatment strategies.
Flow cytometry, crystal violet staining and immunoblotting were used to assess cell cycle arrest, proliferation and apoptosis in lung cancer cell lines after 2-DG treatment and lentivirus infection by shRNA knock down. IHC and western blotting were carried for NSG xenograft model with 2-DG treatment and lentivirus infection by shRNA knock down.
Knocking down Kras down-regulated the glycolytic enzyme hexokinase II (HK2) in KP2 (mouse lung cancer cell line with Kras mutation and p53 deletion) and H23 (human lung cancer cell line with Kras mutation and p53 mutation) cell lines. Genetic studies revealed that HK2 was required for the human and mouse lung cancer cell growth in vitro and in vivo. Our pharmacological studies confirmed that 2-DG, an inhibitor of HK2, inhibited human and mouse lung cancer cell growth through inducing cell apoptosis and autophagy.
HK2 is a promising treatment target for NSCLC with Kras activating and p53 function loss.
KeywordsNSCLC HK2 Kras 2-DG Apoptosis
More than one million people in the world die from lung cancer every year, so which is the leading cause of cancer mortality in human [1, 2]. Usually, lung cancer is defined in two types, small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC). NSCLC accounts for approximately 85 % of all the lung cancers at present. More than 70 % of NSCLC patients are advanced disease, and only 16 % can achieve the 5-year survival rate. For early stage, surgery combining with chemotherapy is the current standard of care. For stage III/IV of NSCLC, platinum-based combined chemotherapy is the standard approach, but chemotherapy has strong side effects to patients , so it is necessary to pursue new therapy strategies.
The most common mutations identified in human NSCLC are Kras mutations (10–30 %) and loss of function point mutations in p53 (50–70 %) . Furthermore, for the patients harboring EGFR mutations (17 %) , resistant to EGFR tyrosine kinase inhibitors (TKIs) therapy, which has been proposed that the mutations in Kras and loss of functions in p53 may be the mechanism of primary resistance to EGFR TKI [6, 7]. And many researches demonstrated that the lung cancer patients, harboring mutations in Kras or loss of functions in p53, have poor clinical outcomes to chemotherapy and EGFR TKIs [8–10]. Therefore, inhibition of Kras expression or stimulation of p53 functions is attractive therapeutic strategy for this disease. However, it has, so far, been unsuccessful to attempt to develop drugs that target oncogenic Kras and convert mutant p53 proteins to a functional state [11–13], so we try to find Kras and p53 downstream therapeutic targets.
The well-established Kras gene encodes a small GTP-binding protein that serves vital roles not only in mediating cell growth, differentiation and apoptosis but also in regulating cell metabolism [14, 15]. Oncogenic Kras causes mitochondrial metabolism and the generation of reactive oxygen species (ROS) through regulation of the ERK-MAPK signaling pathway . And it also mediates cancer metabolism by stimulation of glucose uptake and driving glucose intermediates into pentose phosphate pathways (PPP) and the hexosamine biosynthesis . Activation of oncogenic Kras leads to mitochondrial dysfunction, causing decreased respiration, and increased glycolysis . Therefore, oncogenic Kras might promote and maintain tumor growth by increasing the Warburg effect and anabolic (biosynthesis) pathways.
Hexokinases (HKs) catalyze the first essential step in glucose metabolism by phosphorylation of glucose to glucose-6-phosphate (G-6-P) . There are four major isoforms (HK1, HK2, HK3, and HK4) characterized in mammalian tissue . Among these, only the high level of HK2 expression has wildly been observed in cancer cells and is associated with poor overall survival in cancer patients [20, 21]. Patra et al.  found HK2 overexpression in mutant Kras overexpression and p53 knock out transgenic mouse models. Now our genetic studies in details address that HK2 is required for lung cancer cell growth in mouse KP2 cell (mouse lung cancer cell line with Kras mutation and p53 deletion) and human H23 cell (Human lung cancer cell line with Kras mutation and p53 mutation) in vitro and in vivo. And our pharmacological studies furthermore suggest that HK2 is one of the most important potential therapy targets for Kras overexpression and p53 function lose-driven lung cancer.
Cell lines, cell culture and reagents
Mouse lung cancer cell (KP2) line was generous gifted from Prof. Taylor Jackson. Human lung cancer cell (H23) was obtained from American Type Culture Collection. KP2 and H23 cells stably expressing GFP-LC3. All these cells were cultured in DMEM supplemented with 10 % FBS. 2-DG was purchased from Sigma-Aldrich and formulated in PBS.
Plasmids and viral transfections
PLZW plasmids expressing human HK2 were obtained from Addgene. All other shRNAs were from the BioMedical Genomics Center at The University of Minnesota. These are lentiviral shRNAs and are as follows: Kras (TRCN0000034384 and TRCN0000055356; TRCN0000055357 for human and mouse), HK2 (TRCN0000037670 and TRCN0000037609; TRCN0000037669 for human; and TRCN0000037672 for mouse), AKT (TRCN0000039793; TRCN0000039794; TRCN0000039796 for human and mouse). In this study, we used the calcium phosphate transfection method to transfect vector into actively growing HEK-293T cells as described previously . In briefly, the pLKO.1 vector backbone as the negative control vector has no hairpin insert. Firstly, shRNA-encoding plasmids need to be mixed thoroughly with envelope and packaging plasmids (VSVG, REV and pMDL) and then co-transfected into adherent HEK-293T cells using the calcium phosphate method. Collected virus-containing supernatant at 36 h after transfection, and centrifuged to remove cell and cell debris, and then infected the target cell with 8 μg/ml polybrene. To generate stable cell lines, cells were selected with 8 μg/ml puromycin 24 h later and knockdown efficiency was detected by immunoblotting.
Cell growth evaluation and clonogenic survival assay
Seeded 2 × 105 cells in each well in 6-well plates to analyze cell growth by 2-DG treatment. Incubated the cells overnight for cells attaching. To study whether the inhibition of cell growth treated with 2-DG is dose and time dependent, we collected cells treated with different concentration of 2-DG (2.5, 5,10, 10 mg/ml) for 48 h and cells treated with 10 mg/ml 2-DG for different time (12, 24, 48, 60, 72 h). Stained the cells with 0.25 % (w/v) trypan blue and counted. Washed the cells twice with PBS, and fixed in 10 % formalin for 10 min at room temperature, and then stained with methanol (10 % v/v) containing crystal violet (0.1 % w/v). Removed excess crystal violet and washed several times with distilled water and dried them. For clonogenic survival assay, seeded 2 × 104 cells in each well of 6-well plate with stably expressing shRNA. After 1 week, fixed cell colonies in 10 % formalin and stained with crystal violet (0.1 % w/v).
Washed the cells twice with ice-cold PBS and then lysed with ice-cold lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM MgCl2, 5 mM EGTA pH 8.0, 1 mM dithiothreitol, 0.5 % Triton X–100, 10 % glycerol, 1 mM Na3VO4, 1 μM microcystin–LR and protease/phosphatase inhibitor cocktail) for 30 min on ice. The lysates were centrifuged at 12,000 rpm for 5 min at 4 °C. Equivalent samples were resolved by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5 % non-fat milk in PBS and then probed with indicated primary antibody overnight at 4 °C. In this study, the following antibodies were used: Kras (Millipore), HK2 (Cell signaling technology), Cleaved PARP (human) (Cell signaling technology), Cleaved PARP (mouse) (Cell signaling technology), LC3II (Cell signaling technology), Alpha-tubulin (Santa Cruz Technologies) and all of them were used at 1:1000 dilution. Then, primary antibody was detected with HRP-conjugated anti-mouse or anti-rabbit secondary antibody (GE Healthcare). Western HRP substrate was from Millipore.
All immunohistochemical analyses were carried out as previously described . In this study, the following antibodies were used: LC3II, cleaved caspase-3 (Cell Signaling) and Ki67 (Millipore), and all of them were used at 1:100 dilution.
Xenograft mouse model and treatment
The animal protocol was approved by the Institutional Animal Care and Use Committee of the University of Minnesota, and carried out at the Hormel Institute’s AAALAC-accredited animal facility. Subcutaneously injected 1 × 106 cells (suspended in 100 μl of PBS) into the lower flank of NSG mice (005557 from The Jackson Laboratory; http://jaxmice.jax.org/strain/005557.html). To further study the Kras and HK2 function in vivo, the mice were injected with control, Kras knockdown KP2 cells, HK2 knockdown KP2 cells, or rescuing HK2 KP2 cells, monitored for tumor progress and euthanized all mice at 4 weeks after injection. Tumors were weighed and photographed. Once xenograft tumors for the study of 2-DG treatment were established (the tumor volume is about 50–100 mm3), two groups of mice were treated with PBS (Control) or 2-DG (800 mg/kg in PBS) by I.P. injection (daily for 15 days). Mice were euthanized, and tumors were dissected, weighed and fixed in 10 % formalin for histopathology and IHC analysis.
Statistical significance is determined by Student’s t test or ANOVA analysis with Graphad Prism (v.5). P < 0.05 is considered to be statistically difference, and P < 0.01 is significant difference.
Knockdown of oncogene Kras suppresses lung cancer cell growth and down regulates HK2 expression in vitro and in vivo
Although oncogenic Kras is one of the most important of the potential targets for drug development, so far, it has been unsuccessful to attempt to develop drugs that directly target oncogenic Kras. Therefore, it is very important for Kras-driven lung cancer therapy to pursue the key gene regulated by Kras, and to find its inhibitors or drugs. To decipher the relations of Kras and HK2, we checked HK2 protein by immunoblotting in Kras-knockdown cells, KP2 and H23. As shown in Fig. 1a, HK2 is significantly decreased in Kras-knockdown KP2 and H23 cells compared with the mock group. HK2 protein level had no significant change when shKRAS-01 and shKRAS-02 did not knock down Kras protein in H23 cells in Fig. 1b.
HK2 is required for lung cancer cell growth in vitro and in vivo
2-DG, HK2 inhibitor, suppresses growth of mouse and human lung cancer cells
Summary of cell cycle arrest patterns in two lung cancer cells induced by 2-DG
Exposure time (h)
2-DG suppresses tumor growth in vivo
Since 2-DG treatment inhibits cell growth in vitro, we predict the same efficacy of 2-DG in vivo. The NSG mice were subcutaneously injected with KP2 cells and treated with PBS or 2-DG (800 mg/kg BW) by I.P injection for 15 days. Our results revealed that tumor weights in the mice receiving 2-DG were significantly reduced in comparison with the control group (P = 0.0086) (Fig. 4a, b). The significant reduction of ki67-positive cells in 2-DG-treated mice group than in the control showed that 2-DG had inhibited KP2 cell proliferation capacity (P = 0.004) (Fig. 4c, d) in xenograft tumor sections with IHC staining. Increased cleaved caspase 3 detected by IHC in the 2-DG-treated group in comparison with the control confirmed significant induction of KP2 cell apoptosis (P = 0.0083) (Fig. 4c, e). IHC staining of LC3II in 2-DG treatment mice were also significantly induced in compared with those in the control group (P = 0.009) (Fig. 4c, f). Taken together, these studies showed that the 2-DG, HK2 inhibitor, suppresses lung cancer cell growth in vivo.
Many genetic and epigenetic lesions, which were detected in lung cancer, may represent potential therapeutic targets for NSCLC [24, 25]. Five common oncogenes, Kras, EGFR, ALK, ERBB2, and BRAF are represented in more than 50 % of lung adenocarcinomas [26, 27]. The oncogene Kras is the most important potential target of these genes because of its sitting at the apex of multiple growth regulatory cascades. And most of Kras overexpression patients show loss function of p53 (50–70 %) . Therefore, the strategy to target Kras and p53 may be the effective therapeutic method for NSCLC. In this study, we use shRNA method to down-regulate the expression of oncogenic Kras in KP2 and H23 cells. Our results suggest that knockdown of Kras reduces cell proliferation in vitro and decreases tumorigenesis in vivo which are in consistent with previous reports in the NSCLC cell lines  and pancreatic cancer cell line CAPAN-1 both harboring oncogene Kras . Unfortunately, the previous studies certificated that the clinical trials of Kras inhibitors, aimed at Kras C-terminal farnesylation, did not show any significantly statistical difference [30, 31] and the clinical trials of inhibitors against downstream signaling proteins RAF and MEK were also not successful [32–34]. Therefore, focusing on other new therapeutic targets or signal pathway for NSCLC may be an effective Achilles heel.
So far, our genetic studies show that the gene HK2 is required for the growth of Kras overexpression and p53 function lose-driven lung cancer cells in vitro and in xenograft models. Upon a conditional knockdown of HK2, cancer cells growth was significantly inhibited. Moreover, Wolf et al. found HK2 knockdown by shRNAs inhibits tumor growth in a glioblastoma xenograft model . Taken together, these results are consistent and reveal the HK2 involved in multiple types of carcinoma.
Given that HK2 plays the crucial role for cell growth in Kras overexpression and p53 function lose-driven lung cancer cells in vitro and in vivo, pharmacologically targeting HK2 may be explored as an effective therapy for NSCLC. 2-Deoxy-d-glucose (2-DG) as an inhibitor of HK2 is a glucose molecule and cannot undergo further glycolysis. This drug also showed promising anticancer effects in preclinical models . Previous studies in vitro show that 2-DG is effective to inhibit some cancer cells growth [41, 42]. In vivo, 2-DG combining with other drugs such as paclitaxel and Adriamycin also could significantly decrease tumor proliferation in mice bearing human MV522 lung tumor carcinoma and osteosarcoma . However, some later studies indicated that 2-DG treatment did not show significant antitumor activity as a single agent in vivo in some kinds of cancer cell lines [43–45]. Thus the effect of 2-DG against cancer is controversial. In our study, we choose the mouse KP2 cell (Kras mutation and p53 deletion) and human H23 cell (Kras mutation and p53 mutation) with high expression level of HK2 as research models, we found 2-DG not only inhibits KP2 and H23 cell growth in vitro, but also decreases tumor proliferation in SCID mice bearing KP2 lung cancer cells. As shown in Figs. 3 and 4, 2-DG inhibits cell growth and tumor proliferation in vitro and in vivo by inducing tumor cell apoptosis and autophagy through targeting HK2. The role of autophagy in tumorigenesis is complicated because it may represent a protective response during under some stressful conditions such as toxic stimuli, radiation, and chemotherapy [46–48], but also can limit proliferation of cells by facilitating senescence. Thus, our next study will focus on whether autophagy induced by 2-DG in Kras overexpression and p53 function lose-driven NSCLC is cytoprotective response or not cytotoxic. If 2-DG inducing autophagy is a survival response, the strategy that 2-DG combining with the inhibitor of autophagy such as CQ may be a synergistic effective therapy for NSCLC.
Briefly, our genetic and pharmacological studies furthermore suggest that HK2 is one of the most important potential therapy targets and its inhibitor 2-DG is showing promising therapy efficacy in Kras overexpression and p53 function lose-driven malignant lung cancer.
HW and LW performed animal studies, hematoxylin and eosin staining, and immunohistochemistry on prostate cancer samples. HW performed cell culture studies. YZ and JW helped with the cell culture and animal experiments and generated data. DL provided conceptual advice, assisted with the design of animal experiments, and helped to edit the manuscript. YD supplied some experimental materials and provided conceptual advice. All authors read and approved the final manuscript.
This work is supported, in part, by Grants from the Hormel Foundation (Y.D.). China National Nature and Science Foundation (31372489 and 30972231 Degui Lin).
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.View ArticlePubMedGoogle Scholar
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.View ArticlePubMedGoogle Scholar
- Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–53.View ArticlePubMedGoogle Scholar
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.View ArticlePubMedGoogle Scholar
- D’Angelo, SP, Catherine Pietanza M, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR Exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29(15):2066–70.Google Scholar
- Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2011;71:7071–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–72.View ArticlePubMedGoogle Scholar
- Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69:272–8.View ArticlePubMedGoogle Scholar
- Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crino L, Amadori D, Dazzi C. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Int J Mol Sci. 2015;16:747–57.View ArticlePubMed CentralGoogle Scholar
- Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009;102:1–17.View ArticlePubMedGoogle Scholar
- Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol. 2012;19:42–50.View ArticlePubMedGoogle Scholar
- Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.View ArticlePubMedGoogle Scholar
- Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 2012;22:399–412.View ArticlePubMedPubMed CentralGoogle Scholar
- Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010;107:8788–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB, Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049–57.View ArticlePubMedGoogle Scholar
- Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001;276:43407–12.View ArticlePubMedGoogle Scholar
- Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 2011;108:4129–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, Koochekpour S, Saleem M, Huang H, Lu J, Deng Y. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 2014;8:1461–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila). 2009;2:484–95.View ArticleGoogle Scholar
- Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327–43.View ArticlePubMedGoogle Scholar
- Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117:2740–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009;4:e4576.View ArticlePubMedPubMed CentralGoogle Scholar
- Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(Suppl 2):S16–22.View ArticlePubMedGoogle Scholar
- Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011;10:336–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243–7.View ArticlePubMedGoogle Scholar
- Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. 2003;63:5656–68.PubMedGoogle Scholar
- Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459–64.View ArticlePubMedGoogle Scholar
- Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5:1630–6.View ArticlePubMedGoogle Scholar
- Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16:2450–7.View ArticlePubMedGoogle Scholar
- Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456–62.View ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.View ArticlePubMedGoogle Scholar
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.View ArticlePubMedGoogle Scholar
- Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMedGoogle Scholar
- Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208:313–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 2004;16:819–30.View ArticlePubMedGoogle Scholar
- Roberts DJ, Tan-Sah VP, Smith JM, Miyamoto S. Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J Biol Chem. 2013;288:23798–806.View ArticlePubMedPubMed CentralGoogle Scholar
- Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2004;53:116–22.View ArticlePubMedGoogle Scholar
- Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol. 2002;64:1745–51.View ArticlePubMedGoogle Scholar
- Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31–4.View ArticlePubMedGoogle Scholar
- Zhong D, Liu X, Schafer-Hales K, Marcus AI, Khuri FR, Sun SY, Zhou W. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther. 2008;7:809–17.View ArticlePubMedGoogle Scholar
- Zhong D, Xiong L, Liu T, Liu X, Liu X, Chen J, Sun SY, Khuri FR, Zong Y, Zhou Q, Zhou W. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem. 2009;284:23225–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009;16:966–75.View ArticlePubMedGoogle Scholar
- Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19:87–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol. 2013;8:105–37.View ArticlePubMedPubMed CentralGoogle Scholar